CELL INTELLIGENCE · 肿瘤细胞治疗研究

Lisaftoclax 联合伊沙佐米和地塞米松在 CAR-T 后用于不适合移植的复发/难治性超高危多发性骨髓瘤维持治疗：两例病例报告及文献综述

Lisaftoclax combined with ixazomib and dexamethasone after CAR-T for maintenance therapy in transplant-ineligible relapsed/refractory ultra-high-risk

基于纳米抗体的 CAR-T 在肿瘤免疫治疗中的应用（综述）

Application of nanobody‑based CAR‑T in tumor immunotherapy (Review).

用 PD1IL7R 嵌合开关受体在体外增强 CD19/BCMA CAR-T 细胞的抗肿瘤活性

Enhancing the antitumor activity of CD19/BCMA CAR-T cells in vitro with a PD1IL7R chimeric switch receptor.

CAR-T 细胞治疗实体瘤的挑战与进展

The challenges and progress of CAR-T cell therapy in the treatment of solid tumors.

临床试验中 CAR-T 细胞疗法治疗癌症的治疗相关不良事件：系统综述和荟萃分析

Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis.

我们的研究提供了与不同 CAR-T 细胞治疗相关不良事件的全面数据，描绘了完整的毒性特征，并为临床医生选择和 manage 抗肿瘤治疗提供了重要参考。

描绘细胞治疗格局：中国临床试验与监管进展的洞见

Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China.

揭示 T 细胞耗竭：对 CAR-T 细胞治疗的启示与意义

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy.

溶瘤单纯疱疹病毒递送 CD19 和 BCMA 双 CAR 靶点及免疫调节剂以增强联合 CAR-T 细胞治疗实体瘤的疗效

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumo

这些研究表明，新一代 oHSV T7011 可与 CD19 或 BCMA 特异性 CAR-T 细胞联合治疗，有望成为治疗多种实体瘤的有前景的联合疗法。